$CANF
Can-Fite BioPharma Ltd. Stock $canf

$canf Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000121390023024298 Filed on March 30, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$197.0K	$810.0K	$204.0K
YoY Change	-3.43%	-5.04%	36.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.454M	$263.0K	$3.101M
YoY Change	-20.86%	-97.33%	7.08%
% of Gross Profit
Research & Development	$826.0K	$7.763M	$1.131M
YoY Change	-26.97%	101.79%
% of Gross Profit
Depreciation & Amortization	$8.000K	$14.00K	$6.000K
YoY Change	33.33%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$3.280M	$8.026M	$4.232M
YoY Change	-22.5%	-41.39%	14.29%
Operating Profit		-$10.10M
YoY Change		-21.38%
Interest Expense	$64.00K	-$61.00K	-$90.00K
YoY Change	-171.11%	-124.9%	12.5%
% of Operating Profit
Other Income/Expense, Net		-$77.00K
YoY Change		327.78%
Pretax Income	-$3.019M	-$10.17M	-$4.118M
YoY Change	-26.69%	-19.36%	13.35%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.019M	-$10.17M	-$4.118M
YoY Change	-26.69%	-19.36%	13.35%
Net Earnings / Revenue	-1532.49%	-1255.93%	-2018.63%
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share	$0.00	-$0.01	-$6.197K
COMMON SHARES
Basic Shares Outstanding	815.7M shares	815.7M shares
Diluted Shares Outstanding		815.7M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.986M	$2.986M	$4.627M
YoY Change	-35.47%	-35.47%	-44.54%
Cash & Equivalents	$2.978M	$2.978M	$4.390M
Short-Term Investments	$8.000K	$8.000K	$237.0K
Other Short-Term Assets	$6.171M	$6.124M	$14.51M
YoY Change	-57.48%	-60.22%
Inventory
Prepaid Expenses	$1.123M
Receivables
Other Receivables	$1.170M		$929.0K
Total Short-Term Assets	$9.157M	$9.157M	$20.07M
YoY Change	-54.37%	-54.37%	113.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.00K	$126.0K	$185.0K
YoY Change	-77.3%	-31.89%	50.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$126.0K	$126.0K	$185.0K
YoY Change	-31.89%	-31.89%	50.41%
TOTAL ASSETS
Total Short-Term Assets	$9.157M	$9.157M	$20.07M
Total Long-Term Assets	$126.0K	$126.0K	$185.0K
Total Assets	$9.283M	$9.283M	$20.25M
YoY Change	-54.16%	-54.16%	112.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$896.0K	$896.0K	$954.0K
YoY Change	-6.08%	-6.08%	70.05%
Accrued Expenses	$48.00K	$823.0K	$53.00K
YoY Change	-9.43%	-14.09%	23.26%
Deferred Revenue	$783.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.502M	$2.502M	$2.730M
YoY Change	-8.35%	-8.35%	115.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.309M	$2.309M	$3.141M
YoY Change	-26.49%	-26.49%	44.08%
Total Long-Term Liabilities	$2.309M	$2.309M	$3.141M
YoY Change	-26.49%	-26.49%	44.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.502M	$2.502M	$2.730M
Total Long-Term Liabilities	$2.309M	$2.309M	$3.141M
Total Liabilities	$4.811M	$4.811M	$5.871M
YoY Change	-18.05%	-18.05%	70.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$150.8M		-$140.7M
YoY Change	7.23%
Common Stock	$500.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.472M	$4.472M	$14.38M
YoY Change
Total Liabilities & Shareholders Equity	$9.283M	$9.283M	$20.25M
YoY Change	-54.16%	-54.16%	112.67%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.019M	-$10.17M	-$4.118M
YoY Change	-26.69%	-19.36%	13.35%
Depreciation, Depletion And Amortization	$8.000K	$14.00K	$6.000K
YoY Change	33.33%	0.0%	0.0%
Cash From Operating Activities	-$4.723M	-$10.80M	-$6.391M
YoY Change	-26.1%	9.57%	78.77%
INVESTING ACTIVITIES
Capital Expenditures	$4.000K	$9.000K	-$3.000K
YoY Change	-233.33%	-181.82%	-88.46%
Acquisitions
YoY Change
Other Investing Activities	$6.014M	$9.511M	-$14.50M
YoY Change	-141.48%	-165.59%
Cash From Investing Activities	$6.010M	$9.502M	-$14.50M
YoY Change	-141.44%	-165.48%	55680.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$17.71M
YoY Change			525.24%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000		17.71M
YoY Change	-100.0%		525.24%
NET CHANGE
Cash From Operating Activities	-4.723M	-$10.80M	-6.391M
Cash From Investing Activities	6.010M	$9.502M	-14.50M
Cash From Financing Activities	0.000		17.71M
Net Change In Cash	1.287M	-$1.412M	-3.181M
YoY Change	-140.46%	-63.91%	314.19%
FREE CASH FLOW
Cash From Operating Activities	-$4.723M	-$10.80M	-$6.391M
Capital Expenditures	$4.000K	$9.000K	-$3.000K
Free Cash Flow	-$4.727M	-$10.81M	-$6.388M
YoY Change	-26.0%	9.78%	79.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36203
CY2022	dei	Entity Registrant Name EntityRegistrantName	Can-Fite BioPharma Ltd.
CY2022	canf	Weighted Average Remaining Contractual Termsin Years Forfeitedexpired WeightedAverageRemainingContractualTermsinYearsForfeitedexpired
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	10 Bareket Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Kiryat Matalon
CY2022	dei	Entity Address Address Line3 EntityAddressAddressLine3	P.O. Box 7537
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Petah-Tikva
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	4951778
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing 300 Ordinary Shares, no par value *
CY2022	dei	Trading Symbol TradingSymbol	CANF
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	815746293	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1281
CY2022	dei	Auditor Name AuditorName	KOST FORER GABBAY& KASIERER
CY2022	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2978000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4390000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	5001000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	14512000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1170000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	929000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	8000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	237000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9157000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	20068000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	138000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	126000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	185000	usd
CY2022Q4	us-gaap	Assets Assets	9283000	usd
CY2021Q4	us-gaap	Assets Assets	20253000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	896000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	954000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	783000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	818000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	775000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	905000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2502000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2730000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2295000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3070000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2309000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3141000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	815746293	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	815746293	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	815746293	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	815746293	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	154192000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	153929000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1127000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1127000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150847000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140674000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4472000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14382000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9283000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20253000	usd
CY2022	us-gaap	Revenues Revenues	810000	usd
CY2021	us-gaap	Revenues Revenues	853000	usd
CY2020	us-gaap	Revenues Revenues	763000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7763000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9850000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11951000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3143000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3845000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2951000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10096000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-12842000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-14139000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	227000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-304000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10173000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12615000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14443000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10173000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12615000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14443000	usd
CY2021	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	2590000	usd
CY2020	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	715000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10173000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-15205000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-15158000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	815746293	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	553079638	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	358411297	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2442000	usd
CY2020	canf	Warrants Net Of Issuance Expenses WarrantsNetOfIssuanceExpenses	3703000	usd
CY2020	canf	Stock Issued During Period Value Issuance Of Share Capital And Warrants StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants	17683000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	317000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14443000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	6074000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	980000	usd
CY2021	canf	Issuance Of Share Capital Due To Warrants Exercise Net Of Issuance Expenses IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses	11767000	usd
CY2021	canf	Warrants Net Of Issuance Expenses WarrantsNetOfIssuanceExpenses	1307000	usd
CY2021	canf	Stock Issued During Period Value Issuance Of Share Capital And Warrants StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants	8690000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	68000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12615000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	398000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14382000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14382000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	263000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10173000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4472000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10173000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12615000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14443000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-54000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-55000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-9000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	263000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	466000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	355000	usd
CY2022	canf	Increase Decrease In Changes In Fair Value Of Shortterm Investment IncreaseDecreaseInChangesInFairValueOfShorttermInvestment	-229000	usd
CY2021	canf	Increase Decrease In Changes In Fair Value Of Shortterm Investment IncreaseDecreaseInChangesInFairValueOfShorttermInvestment	162000	usd
CY2020	canf	Increase Decrease In Changes In Fair Value Of Shortterm Investment IncreaseDecreaseInChangesInFairValueOfShorttermInvestment	11000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-113000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	46000	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	241000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-128000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4275000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-62000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-63000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-58000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	393000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1595000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-810000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1398000	usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-401000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-130000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	574000	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-279000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10801000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9858000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12063000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000	usd
CY2022	canf	Withdrawalinvestment In Shortterm Deposits Net WithdrawalinvestmentInShorttermDepositsNet	-9511000	usd
CY2021	canf	Withdrawalinvestment In Shortterm Deposits Net WithdrawalinvestmentInShorttermDepositsNet	14500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9502000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14511000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	20457000	usd
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	17683000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20457000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17683000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-113000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-23000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1412000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3878000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5571000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4390000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8268000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2697000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2978000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4390000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8268000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	120000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	29000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	2590000	usd
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	715000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	18000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	23000	usd
CY2022Q4	us-gaap	Shares Issued SharesIssued	300	shares
CY2022	canf	Net Losses NetLosses	10173	usd
CY2022	canf	Cash Flows From Operating Activities CashFlowsFromOperatingActivities	-10801	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	canf	Percentage Of Realization On Ultimate Settlement PercentageOfRealizationOnUltimateSettlement	0.50	pure
CY2022	us-gaap	Short Term Debt Weighted Average Interest Rate Over Time ShortTermDebtWeightedAverageInterestRateOverTime	0.0579	pure
CY2021	us-gaap	Short Term Debt Weighted Average Interest Rate Over Time ShortTermDebtWeightedAverageInterestRateOverTime	0.0053	pure
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1123000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	881000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1170000	usd
CY2022Q4	canf	Contract Liabilities ContractLiabilities	3078000	usd
CY2021Q4	canf	Contract Liabilities ContractLiabilities	3888000	usd
CY2022	canf	Revenue Revenue	810000	usd
CY2022	canf	Revenue Contract With Customer RevenueContractWithCustomer	1	pure
CY2021	canf	Revenue Contract With Customer RevenueContractWithCustomer	1	pure
CY2020	canf	Revenue Contract With Customer RevenueContractWithCustomer	1	pure
CY2022	canf	Aggregate Intrinsic Value Forfeitedexpired AggregateIntrinsicValueForfeitedexpired		usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of Credit Risk: </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b> </b></p>
CY2022	canf	Percentage Of Deposits On Monthly Salary PercentageOfDepositsOnMonthlySalary	0.0833	pure
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	51000	usd
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	53000	usd
CY2020	us-gaap	Severance Costs1 SeveranceCosts1	46000	usd
CY2022	canf	Options Options	27002200	shares
CY2021	canf	Options Options	18422700	shares
CY2020	canf	Options Options	11923400	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	375197640	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	377947640	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	228192286	shares
CY2022	canf	Totalin Dollars TotalinDollars	402199840	shares
CY2021	canf	Totalin Dollars TotalinDollars	396370340	shares
CY2020	canf	Totalin Dollars TotalinDollars	240115686	shares
CY2022Q4	canf	Government Authorities GovernmentAuthorities	47000	usd
CY2021Q4	canf	Government Authorities GovernmentAuthorities	48000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	929000	usd
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	5947	shares
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	5947	shares
CY2022	canf	Percentage Of Outstanding Shares PercentageOfOutstandingShares	0.05	pure
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	290000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	281000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	248000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	234000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47000	usd
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	14	usd
CY2021	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	14	usd
CY2020	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	12	usd
CY2022Q4	canf	Employees And Payroll Accruals EmployeesAndPayrollAccruals	492	usd
CY2021Q4	canf	Employees And Payroll Accruals EmployeesAndPayrollAccruals	603	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	283	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	302	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	775	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	905	usd
CY2015Q1	us-gaap	Payments For Fees PaymentsForFees	1292	usd
CY2015Q1	us-gaap	Payments For Fees PaymentsForFees	1650000	cad
CY2022	us-gaap	Additional Liability Long Duration Insurance Benefit Payment AdditionalLiabilityLongDurationInsuranceBenefitPayment	2000000	cad
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.165	pure
CY2022	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	3000	usd
CY2022Q4	us-gaap	Other Loans Payable OtherLoansPayable	6000	usd
CY2022Q4	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	1500	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	500	usd
CY2018Q1	canf	Distribution And Supply Agreement Description DistributionAndSupplyAgreementDescription	Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.
CY2022	us-gaap	Payments To Suppliers PaymentsToSuppliers	750	usd
CY2022Q4	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	3250	usd
CY2019Q4	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	750	usd
CY2021Q1	canf	Milestone Percentage MilestonePercentage	0.175	pure
CY2021Q1	canf	Signature Date SignatureDate	P2Y
CY2021Q1	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	250	eur
CY2021Q1	canf	Milestone Percentage MilestonePercentage	0.30	pure
CY2021Q1	canf	Royalities Description RoyalitiesDescription	15%-40% royalties on net sales upon regulatory approval for veterinary use.
CY2020Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1350000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	us-gaap	Noninterest Expense Commission Expense NoninterestExpenseCommissionExpense	25000	eur
CY2022	us-gaap	Royalty Expense RoyaltyExpense	10000	eur
CY2022	canf	Patent Agreement Description PatentAgreementDescription	Royalties in a total amount of up to €850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) €50 thousand upon initiation of Phase I studies; (ii) €100 thousand upon initiation of Phase II studies; (iii) €200 thousand upon initiation of Phase III studies; and (iv) €500 thousand upon marketing approval by any regulatory authority.
CY2022Q4	us-gaap	Advance Royalties AdvanceRoyalties	850000	eur
CY2022	canf	Royalty Payments Percentage RoyaltyPaymentsPercentage	0.10	pure
CY2020Q1	canf	Aggregate Purchase Price AggregatePurchasePrice	2.625	usd
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0.1	usd
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2400000	usd
CY2020Q1	canf	Issue Of New Unregistered Warrants IssueOfNewUnregisteredWarrants	22278540	shares
CY2020Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.11
CY2020Q1	canf	Deemed Dividend DeemedDividend	715000	usd
CY2020Q1	canf	Securities Purchase Agreement Description SecuritiesPurchaseAgreementDescription	the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 54,750,000 units, each unit consisting of one Ordinary share, and one warrant to purchase one Ordinary share, at a price of $ 0.05 per unit, and (ii) 45,250,020 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one Ordinary share and one warrant, at a price of $ 0.05 per pre-funded unit.
CY2020Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	5000000	usd
CY2020Q1	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2025-02-10
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	20250000	shares
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1012000	usd
CY2020Q2	canf	Increase Authorized Share Capital IncreaseAuthorizedShareCapital	1000000000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	5000000000
CY2020Q2	canf	Aggregate Warrant Purchased AggregateWarrantPurchased	31000020	shares
CY2020Q2	canf	Aggregate Warrant Purchased AggregateWarrantPurchased	31000020	shares
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1550000	usd
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1550000	usd
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8000000	usd
CY2020Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.08
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3400000	usd
CY2020Q3	canf	Issue Of New Unregistered Warrants IssueOfNewUnregisteredWarrants	25582500	shares
CY2020Q3	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.08
CY2020Q3	canf	Aggregate Numbers Of Ads AggregateNumbersOfADS	0.075	pure
CY2020Q3	canf	Warrants To Purchase Aggregate Shares WarrantsToPurchaseAggregateShares	3837390	shares
CY2020Q3	canf	Exercise Price ExercisePrice	0.08
CY2021Q1	canf	Total Consideration Amount TotalConsiderationAmount	2744000	usd
CY2021Q1	canf	Total Consideration Amount TotalConsiderationAmount	2744000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1050000	shares
CY2021Q1	us-gaap	Accrued Exchange Fee Rebate Current And Noncurrent AccruedExchangeFeeRebateCurrentAndNoncurrent	68000	usd
CY2021Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.07
CY2021Q3	canf	Pre Funded Warrant PreFundedWarrant	0.06
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	usd
CY2021Q3	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.07
CY2021	canf	Aggregate Number Of Ads AggregateNumberOfADS	9997000	usd
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	93000000	shares
CY2021	canf	Issuance Expenses IssuanceExpenses	1307000	usd
CY2022	us-gaap	Accelerated Share Repurchases Initial Price Paid Per Share AcceleratedShareRepurchasesInitialPricePaidPerShare	0.07
CY2021Q4	canf	Stock Issuance Agreement Description StockIssuanceAgreementDescription	On December 20, 2021, the Company entered into a warrant exercise agreement (the “Exercise Agreement”) with an institutional investor who is the holder of certain existing warrants to purchase Company’s ordinary shares in a registered direct offering consummated in August 2021.
CY2021Q4	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	150000000	shares
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	usd
CY2021Q4	canf	Exercise Agreement Description ExerciseAgreementDescription	The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $0.07 per Ordinary share. The Company also paid $875 in placement agent fees and issued unregistered placement agent warrants to purchase 10,500,000 Ordinary shares on the same terms as the warrant. Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	375197640	shares
CY2013Q4	canf	Granted Excess Years GrantedExcessYears	P10Y
CY2022Q4	canf	Future Shares FutureShares	8023000	shares
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	137000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	200000	usd
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	159000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	126000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	266000	usd
CY2020	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	158000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	263000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	466000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	317000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021	canf	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice	3	pure
CY2022	canf	Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.25
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18422700	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8750000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	170500	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.54
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27002200	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.13
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y1M20D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther	27002200	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.13
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y1M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	11071575	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	0.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M4D
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y11M15D
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y5M12D
CY2020	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y11M23D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.02
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.18
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	230	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y8M23D
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26513000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28633000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M1D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13	pure
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	54000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	55000	usd
CY2022	canf	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	54000	usd
CY2021	canf	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	55000	usd
CY2021	canf	Supplemental Noncash Information Related To Lease Liabilities Arising From Obtaining Rou Assets SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets	120000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	54000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	18000	usd
CY2022Q4	canf	Lessee Operating Lease Liability Payment Due LesseeOperatingLeaseLiabilityPaymentDue	72000	usd
CY2022Q4	canf	Imputed Interest Less Imputed Interest ImputedInterestLessImputedInterest	10000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26513000	usd
CY2022	canf	Banks Commissions BanksCommissions	-16000	usd
CY2021	canf	Banks Commissions BanksCommissions	-18000	usd
CY2020	canf	Banks Commissions BanksCommissions	-23000	usd
CY2022	canf	Net Loss From Exchange Rate Fluctuations NetLossFromExchangeRateFluctuations	-54000	usd
CY2022	canf	Other Loss From Shortterm Investment Revaluation OtherLossFromShorttermInvestmentRevaluation	-229000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	4000	usd
CY2020	us-gaap	Other Expenses OtherExpenses	363000	usd
CY2022	canf	Finance Expenses FinanceExpenses	-299000	usd
CY2021	canf	Finance Expenses FinanceExpenses	-22000	usd
CY2020	canf	Finance Expenses FinanceExpenses	-386000	usd
CY2022	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	222000	usd
CY2021	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	24000	usd
CY2020	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	44000	usd
CY2021	canf	Exchange Rate Fluctuations ExchangeRateFluctuations	63000	usd
CY2020	canf	Exchange Rate Fluctuations ExchangeRateFluctuations	27000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	162000	usd
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	11000	usd
CY2022	canf	Finance Income FinanceIncome	222000	usd
CY2021	canf	Finance Income FinanceIncome	249000	usd
CY2020	canf	Finance Income FinanceIncome	82000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-77000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	227000	usd
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-304000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.16	pure
CY2022	canf	Development Area A Percentage DevelopmentAreaAPercentage	0.075	pure
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	157106	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25137000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26348000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1376000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2285000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28633000	usd
CY2022	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	218000	usd
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	241000	usd
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	252000	usd
CY2022	us-gaap	Noninterest Expense Transfer Agent And Custodian Fees NoninterestExpenseTransferAgentAndCustodianFees	675	usd
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	180000000	shares
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
CY2020	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends		usd
CY2020	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2020	canf	Withdrawalinvestment In Shortterm Deposits Net WithdrawalinvestmentInShorttermDepositsNet		usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions		usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2021	canf	Net Loss From Exchange Rate Fluctuations NetLossFromExchangeRateFluctuations		usd
CY2020	canf	Net Loss From Exchange Rate Fluctuations NetLossFromExchangeRateFluctuations		usd
CY2021	canf	Other Loss From Shortterm Investment Revaluation OtherLossFromShorttermInvestmentRevaluation		usd
CY2020	canf	Other Loss From Shortterm Investment Revaluation OtherLossFromShorttermInvestmentRevaluation		usd
CY2022	us-gaap	Other Expenses OtherExpenses		usd
CY2022	canf	Exchange Rate Fluctuations ExchangeRateFluctuations		usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001536196

Files In Submission

Name	View Source	Status
canf-20221231_def.xml	Edgar Link	unprocessable
canf-20221231_pre.xml	Edgar Link	unprocessable
0001213900-23-024298-index-headers.html	Edgar Link	pending
0001213900-23-024298-index.html	Edgar Link	pending
0001213900-23-024298.txt	Edgar Link	pending
0001213900-23-024298-xbrl.zip	Edgar Link	pending
canf-20221231.xsd	Edgar Link	pending
canf-20221231_cal.xml	Edgar Link	unprocessable
f20f2022ex1-1_canfitebio.htm	Edgar Link	pending
f20f2022ex12-1_canfitebio.htm	Edgar Link	pending
f20f2022ex12-2_canfitebio.htm	Edgar Link	pending
f20f2022ex13-1_canfitebio.htm	Edgar Link	pending
f20f2022ex13-2_canfitebio.htm	Edgar Link	pending
f20f2022ex15-1_canfitebio.htm	Edgar Link	pending
f20f2022_canfitebio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
canf-20221231_lab.xml	Edgar Link	unprocessable
f20f2022_canfitebio_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CANF
Can-Fite BioPharma Ltd. Stock $canf

2022 Q4 Form 20-F Financial Statement

#000121390023024298 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CANF Can-Fite BioPharma Ltd. Stock $canf

2022 Q4 Form 20-F Financial Statement

#000121390023024298 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CANF
Can-Fite BioPharma Ltd. Stock $canf